Arthur Machlenkin

Dr. Arthur Machlenkin joined Pluristem in May 2022 and serves as Vice president of Research. He is a biotech industry professional with nearly 20 years of academic and industrial experience at the intersection of drug discovery and development. He was most recently CEO at Pantheon Biosciences, an Israeli early-stage biotechnology company translating bacterial immunity into antiviral platforms and therapeutics. As CEO, he led Pantheon’s vision and strategy, built an international team of top-notch researchers and academic collaborators. Prior to Pantheon, Arthur spent four years at Compugen where he was a Head of Immuno-Oncology (I-O) Research with responsibility for building the I-O infrastructure of the company and for target validation process. Before Compugen, Arthur spent 10 years in Hadassah Medical Center as Principal Investigator. He co-led (with Prof. Lotem) basic and translational research, discovery and development of innovative anticancer cell therapies including adoptive cell transfer and genetically modified tumor vaccines. Arthur has a PhD from Weizmann Institute of Science.